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ABSTRACT OF THE DISSERTATION
Radiosensitization of Head & Neck Carcinoma Cells by Linifanib, A
Receptor Tyrosine Kinase Inhibitor

Heng-Wei Hsu
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, December 2013
Dr. Saied Mirshahidi & Dr. Chien-Shing Chen

Tumor angiogenesis is a hallmark of advanced cancers and promotes invasion and
metastasis. Over 90% of head and neck squamous cell carcinomas (HNSCC) express
angiogenic factors such as vascular endothelial growth factor (VEGF). Since
radiotherapy is one of the most commonly used treatments for HNSCC, it is imperative to
identify the interactions between antiangiogenic therapy and radiotherapy, and to develop
combination therapy to improve clinical outcome. The mechanisms between
antiangiogenic agents and ionizing radiation are complicated and involve many
interactions between the vasculature, tumor stroma and tumor cells. The proliferation and
metastasis of tumor cells rely on angiogenesis/blood vessel formation. Rapid growing
tumors will cause hypoxia, which up-regulates tumor cell survival factors, such as VEGF
and hypoxia-inducing factor-1α (HIF-1α), giving rise to more tumor proliferation,
angiogenesis and increased radioresistance. Thus, agents that target new tumor vessel
formation can modulate the tumor microenvironment to improve tumor blood flow and
oxygenation, leading to enhanced radiosensitivity.
Signal transducer and activator of transcription 3 (STAT3), is a potential
modulator of VEGF expression and regulates cell-cycle progression, angiogenesis,
metastasis and apoptosis. Approximately 80% of HNSCC exhibit up-regulation of

xi

STAT3 expression, which theoretically mediates radio-resistance and chemo-resistance.
Therefore, inhibition of STAT3 may render tumor cells growth arrest and/or apoptosis.
Recently it has been discovered that DNA damage can induce the expression and
secretion of interleukin-6 (IL-6), resulting in the activation of STAT3 signaling pathway.
Therefore, by inhibiting STAT3, one can also inhibit DNA damage repair and induce
apoptosis in tumor cells.
In this project, we tested the feasibility of Linifanib (ABT-869), a multi-receptor
tyrosine kinase inhibitor of VEGF and platelet derived growth factor (PDGF) receptor
families, on radio-sensitization of HNSCC. The results show that Linifanib (ABT-869)
can induce an antitumor effect and radio-sensitize HNSCC cells via inhibition of STAT3
signaling pathway. Combining antiangiogenic targeted agent such as Linifanib (ABT869) with radiation to enhance tumor killing and apoptosis may provide a novel
therapeutic strategy and improve efficacy of radiation against HNSCC in the future.
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CHAPTER ONE
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC), including cancers of the oral
cavity, oropharynx, hypopharynx, pharynx and larynx, is the sixth most common cancer
worldwide with approximately 600,000 new cases diagnosed each year (Saman, 2012).
The risk factors are tobacco and alcohol consumption (Saman, 2012), human
papillomavirus (HPV) (Gillison et al., 2012; Kundu and Nestor, 2012), Epstein-Barr virus
(EBV) (Lui et al., 2009; Ho et al., 2013), areca nut (Tseng et al., 2012), and dietary
factors, like higher red meat consumption (Saman, 2012). Two-third of patients are
presented with advanced disease, a combined modality treatment with surgery, radiation
therapy and chemotherapy is current standard of care (Forastiere et al., 2001).
Surgery can be performed if complete tumor resection is possible (Bonner et al., 2006),
however the majority of patients with advanced stage HNSCC are inoperable. The most
frequent treatment is to combine chemotherapeutic agents with radiation (Pan et al.,
2009). Although concurrent chemo-radiation protocols are effective in treating HNSCC,
treatment outcomes vary considerably and cytotoxic side effects are significant (Yin et
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al., 2011). In addition, tumor control and survival are still unsatisfactory. Even those who
have achieved complete remission have a reported local recurrences incidence of 50% to
60%, and distant metastases develop in 20% to 30% of cases, with the 5-year overall
survival rate less than 50% (Sahu and Grandis, 2011).
Recent studies have focused on the use of novel molecule-targeting agents as they
have non-overlapping side effects and can be incorporated with existing treatment
modality of HNSCC to improve outcome. Targeting epidermal growth factor receptor
(EGFR) becomes a rational approach for HNSCC treatment since higher expression of
EGFR has been associated with resistance to radiation and/or chemotherapy (Bonner et
al., 2006; Vermorken et al., 2008). Cetuximab, a monoclonal antibody against EGFR, is
an FDA-approved targeted agent for the treatment of advanced HNSCC (Kundu and
Nestor, 2012; Vincenzi et al., 2010). Combination of cetuximab and radiation improves
the overall survival in patients with locally advanced HNSCC, compared to radiation
alone (49 months versus 29.3 months, P=0.03) (Bonner et al., 2006; 2010). In order to
provide personalized medicine and continue to improve outcome, other novel targeting
strategies are needed. In the past 5 years, antiangiogenic therapies have seen a rapid
ascent into mainstream clinical practice. Since angiogenesis is a hallmark of advanced
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and metastatic cancers, combining anti-angiogenic agents and radiation seems to be
feasible, and warrants further investigation.

The Role of Angiogenesis in Tumor Growth and Metastasis
Angiogenesis is defined as the process of forming new blood vessels to support
tissue growth. It involves endothelial cell differentiation, proliferation, migration and
cord formation, which lead to tubulogenesis to form vessels (Rahimi, 2006). Four
decades ago, Judah Folkman was the first to demonstrate that angiogenesis is important
for the growth and survival of tumor cells (Folkman, 1971). The relationship between
angiogenesis and tumor growth suggests that both tumor cells and their supporting
endothelial cells are potential targets for cell killing and should be considered when
planning cancer treatment (Menard and Camphausen, 2002). Also, solid tumors will not
grow larger than 2 to 3 mm in diameter in the absence of new blood vessels, and require
angiogenesis to metastasize (Folkman, 1995). Vascular supply is an essential component
of the progressive growth of solid tumors because cells in solid tumors, must receive
oxygen and other nutrients to grow (Folkman, 1976). The “tumor cord” model implied
that hypoxic cells exist in a state of oxygen and nutrient starvation at the limits of the
diffusion range of oxygen, and it was hypothesized that tumor cells could proliferate and
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grow only if they were close to a supply of oxygen from tumor stroma. To increase in
size beyond this passive diffusion-limited state, the growing tumor mass must acquire
new blood vessels. A switch to the angiogenic phenotype allows the tumor to expand
rapidly. This so-called “angiogenic switch” (Hanahan and Folkman, 1996) is regulated by
environmental factors and by genetic alterations that act to either up-regulate
proangiogenic factors (i.e., VEGF and bFGF) and transforming growth factors (TGF-α
and TGF-β) and/or downregulate inhibitors of angiogenesis, i.e., angiostatin, endostatin,
thrombospondin, and IFN-α (Los, 2011). Meanwhile, secretion of proteolytic enzymes,
including matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA),
can break down extracellular matrix and basement membranes and allow endothelial cells
to migrate and organize themselves into pericyte supported tubules, eventually, tumor
cells metastasize out (von Tell et al., 2006). A key feature of these new tumor vessels is
that they are structurally abnormal and differ in their behavior from normal blood vessels.
These incomplete endothelial lining and interrupted basement membranes result in an
increased vascular permeability with extravasation of blood plasma and of red blood cells
expanding the interstitial fluid space and drastically increasing the hydrostatic pressure
(interstitial fluid pressure, IFP) in the tumor interstitium (Vaupel, 2004). Such “leaky”
and inefficient tumor vessels deliver less blood, oxygen, nutrients, and ultimately
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anticancer drugs to the tumor, increasing hypoxic conditions and thereby keeping the
angiogenesis cascade continuously active (Bergers and Benjamin, 2003).
Hypoxic condition (pO2 < 2.5 mmHg) can lead to elevated activity of DNA-repair
enzymes and resistance-related proteins, increased transcription of growth factors, and
genomic changes (genomic instability leading to clonal heterogeneity and selection of
resistant clonal variants, like cancer stem cells) (Vaupel, 2004). This is the most potent
stimulus for induction of VEGF, which occurs by activation of Src kinase (Park et al.,
2012). Src kinase activation leads to an increase in HIF-1α and consequent upregulation
of VEGF expression (Dal Monte et al., 2011). Other growth factors stimulating VEGF
production include insulin-like growth factor (IGF)-I and -II, EGF, and PDGFs. There are
some signaling pathways related to the up-regulation of VEGF, like PI3K/AKT,
RAS/MAPK and STAT pathways (Jasinghe et al., 2008; Wong et al., 2009; Zhou et al.,
2009). Although VEGF causes a large increase in blood vessel formation, these vessels
are immature, tortuous and leaky. The formation of thicker, more stable vessels requires
encapsulation by pericytes that is driven by PDGFR-β signaling. In other words, PDGFRβ can support perivascular cells to maintain tumor vasculature formation (Albert et al.,
2006). Low perfusion rates and hypoxia may then coexist with high nonfunctional
vascular density, creating hypoxic regions. In these regions of hypoxia, endothelial cells
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may up-regulate survival factors to maintain their integrity and prevent apoptosis
(Eberhard et al., 2000). Thus, so-called “angiogenic hot spots” or localized regions of
intense angiogenesis may be created and may be associated with failure of radiotherapy
(Koukourakis et al., 2001).

Vascular Endothelial Growth Factor (VEGF) and Its Receptors:
The Role in HNSCC
VEGF plays a central role in the formation of new blood vessels and its
importance in HNSCC has been well established (Moriyama et al., 1997). The VEGF
family of proteins consists of seven ligands, including VEGF A-E and placenta growth
factor (PLGF) 1 and 2 (Ferrara et al., 2003). PLGF, VEGF-A and VEGF-B are known to
bind VEGFR-1. VEGF-A, VEGF-C and VEGF-D are known to bind VEGFR-2 (Dorsey
and Agulnik, 2013; Tammela et al., 2005). VEGF-C and VEGF-D also bind to VEGFR3, which is expressed by lymphatic endothelial cells and hematopoietic progenitor cells
(Achen et al., 2006; Jussila and Alitalo, 2002). VEGFR-1/FLT-1 (fms-like tyrosine
kinase) and VEGFR-2/KDR/FLK-1 (fetal liver kinase) are primarily involved in
angiogenesis. Previous reports show that among VEGF family proteins, VEGF-A is the
most common and can bind to two receptor tyrosine kinases, VEGFR-1 and VEGFR-2,
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promoting endothelial cell differentiation, migration, survival and induction of matrix
metalloproteinase (MMPs) (Jain, 2005; Rahimi, 2006). VEGFR-1 is more involved in the
development of the vascular system during angiogenesis. VEGFR-2 is the predominant
mediator of the angiogenic functions attributed to VEGF that exerts its mitogenic,
chemotactic, and vascular permeabilizing effects on endothelial cells (Christopoulos et
al., 2011). It also activates signaling pathways such as PI3K/AKT and Ras/MAPK
pathways to help with endothelial cell proliferation and survival (Ferrara et al., 2003).
Meanwhile, tumor cells and stromal cells, like endothelial cells and fibroblasts, can
produce VEGF. Through a paracrine loop, tumor cell VEGF can increase endothelial cell
survival (Harmey and Bouchier-Hayes, 2002). Since VEGF and PDGF receptors, as well
as their ligands, are highly expressed in HNSCC, over-expression of PDGF enhances
tumor formation by stimulating VEGF expression in neovessels and by attracting vesselassociated pericytes (Guo et al., 2003). Dual inhibition of VEGF and PDGF can markedly
decrease angiogenesis and inhibit tumor growth in vitro and in vivo (Choong et al., 2010;
Erber et al., 2004). Therefore, these could be good targets to inhibit angiogenesis for the
treatment of HNSCC.
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Signal Transducer and Activator of Transcription 3 (STAT3): The
Role in HNSCC
STAT3 is a multi-fuctional oncogenic transcription factor, present in a number of
different cancer cells including head and neck cancers (Buettner et al., 2002; Leong et al.,
2003; Yin et al., 2010). It is activated by tyrosine phosphorylation via upstream receptor
that binds to growth factors such as EGF, VEGF, PDGF and interleukin-6 (IL-6) (Garg et
al., 2005). Approximately 80% of HNSCC exhibit up-regulation of STAT3 expression,
which implies it may mediate radio-resistance and chemo-resistance (Greten et al., 2002;
Real et at., 2002).
Constitutive activation of STAT3 in HNSCC is caused by diverse signal
transduction pathways. The frequent activation of TGF-α/EGFR and IL-6/gp130/Jak can
upregulate STAT3 expression in HNSCC (Sriuranpong et al., 2003). Src also plays
causative roles in STAT3 upregulation. Tobacco and EBV infection activate STAT3 in
oral keratinocyte and nasopharyngeal epithelial cells. STAT3 up-regulates the levels of
anti-apoptotic proteins cyclinD1 and c-myc, which result in abnormal proliferation
(Masuda et al., 2002). Other anti-apoptotic proteins, like Bcl-2, Bcl-XL and Survivin, are
also targets of STAT3. Overexpressions of these proteins promote cell growth and
increase chemoradiation resistance. Moreover, it is proposed that these ani-apoptotic
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proteins protect DNA-damaged cancer stem cells from elimination by apoptosis and
thereby allow them to expand clonally (Gerl and Vaux, 2005; Yu and Jove, 2004). In
tumor cells, STAT3 is a positive modulator of VEGF production and secretion, in turn;
VEGF activates STAT3 in endothelial cells, which enhance endothelial cell migration,
vessel formation and metastasis. As for innate and adoptive immune responses, STAT3 is
a negative modulator. Tumor cells expressing constitutively active STAT3 decrease
markedly the level of inflammatory cytokines, like TNF-α, IFN-γ, RANTES and IP-10,
therefore inhibit both acute and adoptive immune responses (Jewett et al., 2006; Wang et
al., 2004). Furthermore, these tumor cells significantly increase the level of
immunosuppressive cytokines and growth factors like VEGF and IL-10, which inhibit the
functions of dendritic cells, natural killer cells and cytotoxic T-lymphocytes. As a result,
tumor cells with constitutive STAT3 activation develop the state of “immune evasion”
(Jewett et al., 2006). Recent findings also suggest that STAT3 is involved in the process
of epithelial-to-mesenchymal transition (EMT), thus, tumor cells acquire the ability to
migrate and metastasize (Christofori, 2006; Thiery, 2002). Taken together, STAT3
orchestrates HNSCC tumor development and progression (Masuda et al., 2010). (Figure
1)
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Figure 1. A proposed mechanism by which HNSCC is addicted to STAT3. Constitutive
activation of STAT3 in HNSCC is caused by diverse signal transduction pathways,
therefore, STAT3 is like the Achilles’ heel of HNSCC and can orchestrate tumor
development and progression. Current Cancer Drug Targets Masauda M. 2010, 10, 117126.
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Radiation and Hypoxia
Radiation-induced DNA double strand breaks trigger cell cycle arrest and cell
death by apoptosis and/or necrosis. Oxygen is known to be a potent radiosensitizer that
can promote reactive oxygen species (ROS)/free radicals production, essential for the
induction of radiation-induced DNA damage (Karar and Maity, 2009). As tumors grow,
the microenvironment lacks an adequate blood supply, leading to regions that are
underperfused and poorly oxygenated or hypoxic (Yeom et al., 2011). This can lead to
radiation resistance as a tumor microenvironment in oxygen deficit can not facilitate
radiation-induced DNA damage. Hypoxic tumor cells are particularly known to upregulate hypoxia-inducing factor 1α (HIF-1α), a key transcription factor which increases
the expression of VEGF (Kung et al., 2000). After radiation exposure, the induction of a
variety of transcription factors can activate transcription of growth factors, cytokines and
cell cycle-related genes involved in multiple pathways and affect tumor cell survival or
alter tumor cell proliferation. As for angiogenesis, radiation exposure can result in
activation of EGFR which can activate PI3K/AKT and STAT3 pathways, and upregulate
VEGF production (Bowers et al., 2001). The release of angiogenic growth factors like
VEGF and FGF have been recognized as part of the radiogenic response of epithelial
tumors (Gorski et al., 1999). Protection of tumor vessels by high VEGF levels could
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thereby contribute to the radio-resistance of tumors (Brieger et al., 2007). It has also been
shown that Hsp90, EGFR, VEGF and AKT are known to play a role in radiation
resistance (Sheridan et al., 1997; Tanno et al., 2004). Radiation therapy itself contributes
to radioresistance by upregulating angiogenic and pro-survival factors, like Bcl-2, Bcl-xL
and Survivin (Ho et al., 2010; Khan et al., 2010). The increased tumor cell proliferation
that is often seen after radiation may be the result of up-regulated angiogenic pathways
(Horsman and Siemann, 2006; Timke et al., 2008). This may lead to factors contributing
to radiation resistance such as increased interstitial fluid pressure and vascular
permeability, decreased tumor perfusion, increased oxygen consumption, increased
hypoxic microenvironment, and up-regulated survival pathways, which makes radiation
less effective (Jain, 2005).

Antiangiogenic Interactions and Radiation
Antiangiogenic agents with radiation have been tested in experimental conditions
with various tumor models, tumor host strains, starting tumor size, final tumor volume
measured, and dosing and scheduling (Hendry, 1999). Tumor size can affect oxygen
tension, nutrient supply, and pH, which are all factors in determining radiation response
(Horsman and Siemann, 2006). As tumor size increases, oxygen tension and pH decrease
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because of a greater demand for oxygen and nutrients, and glycolysis dominates, leading
to acidosis (Vaupel, 2004). A previous study also showed that radiation dose required to
achieve the same biologic effect is around 3 times higher in the absence of oxygen than in
its presence, the so-called “oxygen enhancement effect” (Gray et al., 1953).
Antiangiogenic therapy produces a specific “vascular normalization window”, a break
when function, structure of tumor blood vessels and microenvironment temporarily
become normalized (Jain, 2005). Since tumor growth and angiogenesis are part of a
codependent cycle and antivascular treatments can break this cycle and prevent
revascularization after radiation (Wachsberger et al., 2003), the potential function behind
this, is to decrease interstitial fluid pressure (IFP) in tumor tissues and increase blood
perfusion, so that antitumor drugs can easily penetrate into the tumors. Additionally, it
will temporarily overcome hypoxia, improve oxygenation to produce more free radicals,
result in more DNA damage, apoptotic cell death and increase the sensitivity to
radiotherapy (Tong et al., 2004). Therefore, the alternation of radiotherapy and short term
antiangiogenic therapy is what produces this seemingly paradoxical effect of
antiangiogenic therapy via vascular normalization. The concurrent administration of
radiotherapy and contiguous antiangiogenic therapy will not produce a decrease in IFP
and increased blood perfusion.
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Central Hypothesis
The central hypothesis of our project is that, Linifanib (ABT-869), a
VEGFR/PDGFR multi-receptor tyrosine kinase inhibitor, can induce an antitumor effect
and radiosensitize HNSCC cells via inhibition of STAT3 signaling pathway and
augmenting DNA double strand break in tumor cells.

Significance
Angiogenesis plays an important role in the pathogenesis of HNSCC. VEGF and
its receptors are expressed in most cases of HNSCC, and multiple preclinical studies have
shown that these markers are associated with tumor progression, changes in microvessel
density and development of lymph node metastasis (Hicklin and Ellis, 2005). Previous
animal studies demonstrated that inhibition of VEGF markedly decreases angiogenesis
and tumor growth (Kim, 1993). STAT3 is a potential modulator of VEGF expression and
regulates cell differentiation, cell-cycle progression, angiogenesis, metastasis and
apoptosis (Garg et al., 2005). The mechanism of Linifanib (ABT-869), a VEGF/PDGF
receptor tyrosine kinase inhibitor, combined with radiation therapy as a radiosensitizer on
STAT3 signaling pathway and DNA damage response has not yet been identified in
HNSCC. Our study’s contribution is significant; because, for the first time, it defines the
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mechanism for the role of ABT-869 in the regulation of STAT3 pathway in HNSCC, it
will be expected to lead to further research on STAT3 signaling mechanism in
pharmacology. In addition, the positive effects of ABT-869 have been observed in the
treatment of leukemia and other solid tumors, such as breast, liver, lung and colorectal
cancers. Identification of mechanisms underlying ABT-869 combined with radiation
suppression of STAT3 signaling pathway could provide an effective therapeutic for
HNSCC treatment in the future.
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CHAPTER TWO
LINIFANIB (ABT-869) ENHANCES RADIOSENSITIVITY OF
HEAD AND NECK SQUAMOUS CELL CARCINOMA CELLS

By

Heng-Wei Hsu, Daila S. Gridley, Paul D. Kim, Shaoyan Hu,
Rosalia de Necochea-Campion, Robert L. Ferris, Chien-Shing Chen, Saied Mirshahidi

This paper has been published by Oral Oncology. 49:591-597, 2013.
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Abstract
Novel targeted therapeutic strategies to overcome radio-resistance of cancer cells
traditionally treated with radiation may improve patient survival with the added benefit of
reduced systemic toxicity. Herein, we tested the feasibility of Linifanib (ABT-869), a
multi-receptor tyrosine kinase inhibitor of members of vascular endothelial growth factor
(VEGF) and platelet derived growth factor (PDGF) receptor families, on radiosensitization of head and neck squamous cell carcinoma (HNSCC). UMSCC-22A and
UMSCC-22B cells were treated with Linifanib and γ-radiation response was determined
as well. Cell viability, cytotoxicity, apoptosis induction and cell cycle distribution were
examined by MTT assay, colony formation assay and flow cytometry. In addition,
expression of STAT3 and downstream signaling proteins were assessed using western
immunoblotting. To evaluate DNA double strand break γH2AX was used as a marker.
Treatment with Linifanib resulted in cell growth inhibition, G2/M cell cycle arrest,
induction of cell death via apoptosis, reduced phosphorylation of STAT3, which has been
linked to radio-resistance, lower expression of cyclin D1, survivin, increased PARP
cleavage and γH2AX expression. In addition, Linifanib overcame the radio-resistance of
the cell lines and significantly enhanced radiation-induced cytotoxicity (p < 0.05). These
data suggest the possibility of combining targeted therapeutic such as Linifanib with

17

radiation to enhance inhibition of cell growth and apoptosis in HNSCC cells. Thus, it
may provide a novel therapeutic strategy and improve efficacy of radiation against
HNSCC in the future.

Introduction
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common
epithelial malignancy arising in the upper aerodigestive tract, which includes cancers of
the oral cavity, oropharynx, hypopharynx, pharynx and larynx. It is the sixth most
common cancer worldwide, with approximately 600,000 new cases diagnosed each year
(Jemal et al., 2009). Despite advancements in therapeutic regimens, up to 50% of
HNSCC patients will experience treatment failure, patients who have frequent recurrence,
the median survival rate will limit less than 1 year (Cooper et al., 2004). The standard
treatment for loco-regional disease involves surgery and/or radiotherapy in either the neoor adjuvant setting. Concurrent chemoradiation is frequently used as primary treatment
for patients with advance-stage disease, but only a portion of patients have durable
responses to cisplatin-based chemoradiation. In addition, cisplatin has a number of sideeffects that can limit its use (Bernier et al., 2004; de Castro et al., 2007).
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Targeted biological therapies that selectively interfere with cancer cell growth
signals may improve patients’ survival by enhancing the effects of radiation, with the
added benefit of reduced systemic toxicity (Yin et al., 2011). Based on retrospective
cohort study, overexpression of epidermal growth factor receptor (EGFR) correlates with
worse clinical outcome, making it a logical therapeutic target (Agra and Carvalho, 2008).
However, the majority of these tumors fail to respond to EGFR inhibitors. Presence of
EGFR variant III, overactivation of the Ras/MAPK, STAT3 and PI3-K/mTOR pathways
independent from EGFR by other stimuli such as hypoxia-inducible factor-1α (HIF-1α
), which upregulates vascular endothelial growth factor (VEGF) expression, are potential
reasons for response failure (Matta and Ralhan, 2009).
Signal transducer and activator of transcription 3 (STAT3), an oncogenic
transcription factor, is present in a number of different cancer cells including head and
neck cancers (Buettner et al., 2002; Leong et al., 2003; Yin et al., 2010). It is activated by
tyrosine phosphorylation via upstream receptor that binds to growth factors such as
epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), plateletderived growth factor (PDGF) and interleukin-6 (Garg et al., 2005). It is also a potential
modulator of VEGF expression and regulates a variety of critical functions, including cell
differentiation, cell-cycle progression, angiogenesis, metastasis and apoptosis (Sternberg
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and Licht, 2005). Approximately 80% of HNSCC exhibit up-regulation of STAT3
expression, which theoretically mediates radio-resistance and chemo-resistance as
demonstrated in pancreatic and breast cancer studies (Greten et al., 2002; Real et al.,
2002). Therefore, inhibition of STAT3 may render tumor cells growth arrest and/or
apoptosis. In addition, it has been shown that STAT3 blockade in tumor cells resulting to
increased expression of proinflammatory chemokines and cytokines, which led to
subsequent activation of innate and adaptive anti-tumor immunity (Wang et al., 2004).
Linifanib (ABT-869) is a novel ATP-competitive receptor tyrosine kinase
inhibitor in the vascular endothelial growth factor (VEGF) and platelet derived growth
factor (PDGF) receptor families. It is under active clinical development primarily in solid
tumors. Previous studies had shown that Linifanib can inhibit PI3K/AKT, RAS/MAPK
and STAT pathway in acute myeloid leukemia (AML) (Wong et al., 2009; zhou et al.,
2009), and in combination with mTOR inhibitor can inhibit VEGF expression in several
types of cancers (Jasinghe et al., 2008; Semenza, 2003).
In search for novel targeted therapeutic strategies to overcome radio-resistance of
cancer cells, we investigated the role of ABT-869 on radio-sensitization in HNSCC. To
the best of our knowledge, the effect of ABT-869 on radio-sensitization of head and neck
cancer cells has not yet been reported. Furthermore, this study aimed to examine whether
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STAT3 signaling pathway could be inhibited by ABT-869, as a new therapeutic strategy
to reduce radio-resistance of HNSCC. We found that ABT-869 enhances the radiationinduced inhibition of proliferation and apoptosis in two HNSCC cell lines. In addition,
Linifanib reduces phosphorylation of STAT3, which has been linked to radio-resistance.
Therefore, Linifanib may offer a new therapeutic strategy to reduce radio-resistance of
HNSCC.

Materials and Methods
Cell Culture and Reagents
Radio-resistant HNSCC cell lines were used for this study. UMSCC-22A (SCC22A) and UMSCC-22B (SCC-22B) originated from the same patient’s hypopharynx, but
were derived from primary tumor and metastatic cervical lymph node, respectively. The
original tumor grade for SCC-22A was T2N1M0, for SCC-22B was T2N1M0 as well
(Zhao et al., 2011). Linifanib (ABT-869) was kindly provided by Abbott Laboratories,
Abbott Park, IL.

Cell Viability Assay
The cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
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supplemented with 10% fetal bovine serum, 100 U/mL penicillin G and streptomycin and
1% nonessential amino acids. All cells were cultured in a humidified atmosphere of 5%
CO2 at 37 oC. Both cells were seeded in triplicate at 8000 cells/well in 96-well plates.
After growth overnight, the cells were then treated for 48 h and 72h at 37°C with varying
doses (0 [control], 5, 10, 20 and 40 M) of ABT-869. Cell viability was assessed with 3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT reagent, Roche
Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. The plates were
read on a microplate reader (Bio-Rad Model 3550). The similar outcomes were observed,
in a dose- and time-dependent manner, the shown result was for 48 h. The IC50 values
(50% growth inhibition) were determined for each cell line and displayed as mean ± SEM
from at least 3 experiments.

Clonogenic Survival Assay
Cells were exposed to IC25 & IC50 of ABT-869 for 12 hours before-irradiation
with a dose of 2, 4 or 8 gray (Gy) at a dose rate of 1.678 Gy/min, using a 60Co source
(Eldorado machine, Atomic Energy of Canada Ltd, Ottawa, Canada). Culture media was
replaced with fresh media the next day. Colonies were stained with crystal violet after 12-
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14 days, and the number of colonies containing at least 50 cells was counted. Each
experiment was done in triplicate.

Cell Cycle Analysis
Cells (5x105) were exposed to ABT-869 (20 M) or radiation (4 Gy). After 24 &
48 hrs cells were collected, fixed with 75% ethanol, then treated with propidium iodide
(PI) and ribonuclease staining buffer (BD Pharmingen) according to the manufacturer's
protocol. Samples were analyzed by flow cytometry (FACSCaliburTM; Becton Dickinson,
Franklin Lakes, NJ). For radio-sensitization experiments, cells were treated with ABT869, irradiated (4 Gy) and analyzed after 24 & 48 hrs.

Analysis of Apoptosis
Cell death by apoptosis was evaluated by trypan blue dye exclusion using light
microscopy (Olympus IX70, Olympus America Inc., PA) and Annexin-V & PI apoptosis
detection kit (BD Biosciences, San Jose, CA). Briefly, cells were treated the same as for
the cell cycle analysis. After 24 hrs cells were stained with trypan blue (Thermo
Scientific) for 2 hrs and then tested under the light microscope (100X & 400X). Also
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treated cells were stained with FITC-conjugated Annexin-V in the presence of PI
analyzed by flow cytometry. Annexin V+ cells were scored as apoptotic cells.

Western Immunoblotting
The treatment protocol used was the same as for the cell cycle analysis. Twentyfour hours after radiation treatment the cells were harvested, washed and resuspended in
NP-40 lysis buffer. Whole cell lysates (40 μg) were separated through 10-12% sodium
dodecyl sulfate (SDS) polyacrylamide gels under denaturing conditions and transferred to
polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, CA). The
membranes were blocked and incubated with the following antibodies; Phosphor-STAT3,
STAT3 and cPARP (Cell Signaling Technologies, Beverly, MA), cyclin D1, Bcl-2, BclxL, Mcl-1, AIF (Santa Cruz Biotechnology, Santa Cruz, CA), Survivin (Novus, Littleton,
CO), γH2AX (EMD Millipore, Billerica, MA) and HRP-conjugated anti-rabbit IgG
antibody (Cell Signaling Technologies, Beverly, MA). Data were normalized to
corresponding values of GAPDH densitometry.

Statistical Analysis
Each assay was performed at least three times as independent experiments.
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Statistical analyses were done with two-tailed Student’s t-test and performed with Prism
5.01 software (GraphPad Software, San Diego, CA). A p-value of <0.05 was considered
as statistically significant.

Results
Effect of ABT-869 on Cell Growth Inhibition
To evaluate the cytotoxic effect of ABT-869 on SCC-22A and SCC-22B cell
lines, MTT assay was used. ABT-869 induced a significant growth inhibition in a dosedependent manner (Figure 2). IC50 for these cell lines were 21.2 and 19.4 M,
respectively.
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Figure 2. Growth inhibition curve of HNSCC cell lines after ABT-869 treatment. Cells
were treated with increasing concentration of ABT-869 for 48 hr. Live cells were
quantitated by MTT assay. Data are displayed as mean ± SEM from at least 3
experiments.
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ABT-869 Enhances the Antitumor Growth Effect of Radiation
To determine whether ABT-869 enhances radiation-induced cell death in
HNSCC cells, the relatively radiation–insensitive (a 50% killing dose is approximately 8
Gy) SCC-22A&B cells were exposed to ABT-869 for 12 hr followed by radiation (2, 4,
or 8 Gy). The impact of the single and combination treatments on cell proliferation was
then measured by clonogenic cell survival assay. Figure 3 shows that the surviving
fraction at 4 and 8 Gy for ABT-869 treated cells was significantly lower than that of
untreated cells (p < 0.05). This observation suggests that the growth inhibition effect of
ABT-869 could overcome radio-resistance and significantly enhance the effect of
radiation.
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Figure 3. Radio-sensitization effect of ABT-869 on HNSCC cells. SCC-22A & B cells
were plated and exposed to ABT-869 for 12 hr followed by single radiation dose of 2, 4,
or 8 Gy. Colony formation picture was shown above. Survival fraction was assessed at
12-14 days after irradiation. Data are the mean ± SEM of 3 independent experiments.
Asterisks represent significant difference as compared to untreated control group (*p <
0.05, **p < 0.01).
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ABT-869 Induces G2/M Cell Cycle Arrest and Increases Sub-G0
Population Alone and Enhances when Combined with Radiation
The observed inhibition of cell growth by ABT-869 could be the result of the
induction of cell cycle arrest and/or apoptosis. To examine this, SCC-22A&B cells were
treated with ABT-869 for 24 or 48 hr. The percentages of cells were then examined by
flow cytometry after PI staining (Figure 4A&B). Compared to control group, we
observed significant accumulation in G2/M phase in SCC-22A (42.2% versus 23.4% in
control) and in SCC-22B cells (24.6% versus 17% in control), after ABT-869 treatment,
indicating that a higher number of cells were blocked in a more radiosensitive phase of
the cell cycle. In addition, ABT-869 treatment increased sub-G0 population in SCC-22A
(14.3% versus 4.4% and 22.6% versus 5.2% in control) and SCC-22B (21.6% versus
8.6% and 31.4% versus 12% in control) after 24-48 hr, respectively. Interestingly,
radiation alone induced only a transient arrest at G2/M phase at 24 hr. In contrast, the
combination treatment blocked recovery from radiation-induced cell cycle arrest in SCC22A and caused higher accumulation of sub-G0 population in SCC-22B cells, compared
to radiation alone (48 hr). Next we tested whether ABT-869 enhances the effect of
radiation on sub-G0 population. Cells were treated (12 hr) with ABT-869 prior to
radiation (4Gy) and collected 24 hr later. As shown in Figure 4C, ABT-869 in
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combination with radiation increased sub-G0 population by around 2 fold in both cell
lines, compared to radiation alone, confirming that ABT-869 sensitized the cells to
irradiation, hence the synergistic effect of the two treatments.
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Figure 4. The effects of ABT-869 on cell cycle distribution. (A) SCC-22A and (B) SCC22B were treated with ABT-869 20 M combined with radiation and analyzed 24 or 48
hrs later. (C) SCC-22A & B cells were pre-treated with ABT-869 20 M for 12 hrs, then
irradiated at 4 Gy. Cells were harvested 24 hrs later. The percentages of cells were
determined by flow cytometry after PI staining. Data are the mean ± SEM of 3
independent experiments. (*p < 0.05, **p < 0.01)
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ABT-869 Induces Cell Death via Apoptosis
To confirm that the observed ABT-869-induced cell growth inhibition is by
apoptotic death, cells were treated with either ABT-869, radiation, the combination and
stained with trypan blue dye exclusion or Annexin-V and PI. We clearly observed
increased trypan blue dye uptake by cells (dead cells) and morphological changes
considered dead by apoptosis (cell shrinkage, cytoplasmic blebbing, cytoplasmic
condensation and irregular shape) in the combination group compared with untreated,
radiation and ABT-869 alone groups (Figure 5A). We then performed Annexin-V and PI
staining to confirm and determine apoptotic population changes. ABT-869 treatment
increased the apoptotic population by 4.61 and 3.11-fold and by 9.15 and 5.33-fold
increase in combination in SCC-22A & B cells, as compared to untreated and radiation
alone groups respectively (Figure 5B). Apoptotic cell death after combination treatment
was significantly higher (p< 0.05-0.01) than that caused by either of the agents alone.
This was also consistent with increased sub-G0 population (Figure 4C). These data
suggest that apoptosis could be a major contributor in the ABT-869-caused cell growth
inhibition and synergistically enhanced the antitumor growth effect of radiation in both
cell lines.
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Figure 5. ABT-869 can induce cells to undergo apoptosis. SCC-22A & B cells were pretreated with ABT-869 20 M for 12 hrs, or in combination with 4 Gy radiation. Cells
were harvested 24 hrs after radiation. (A) Light microscopy (100X & 400X) showed that
ABT-869 treated and combination group resulted in morphological changes, decreased
cell numbers and more cell death. Trypan blue stain positive cells were considered as
dead cells. (B) Annexin V and PI staining were used and Annexin V positive cells were
counted as apoptotic cells. Data are the mean ± SEM of 3 independent experiments (*p <
0.05, **p < 0.01).
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Using Stattic as Positive Control to Compare the Apoptotic Effects
Induced by ABT-869
Stattic is a well known STAT1 and STAT3 inhibitor in previous literature (Bill et
al., 2010), we further used it as positive control to evaluate whether the apoptotic effects
caused by Stattic is similar to those by ABT-869. We first determined its IC50 after 48
hrs treatment for both SCC-22A&B was around 6 μM. Cells were treated with either
ABT-869 or Stattic IC50 concentration for 24 hrs. Flow cytometry was performed to
determine apoptotic population changes like previously described. The data showed that
ABT-869 can induce similar amount of cell apoptosis like Stattic. (Figure 6)
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Figure 6. ABT-869 can induce similar apoptotic population changes like Stattic. Cells
were treated for 24 hrs. Annexin V and PI staining were used and Annexin V positive
cells were counted as apoptotic cells. Data are the mean ± SEM of 3 independent
experiments (*p < 0.05, **p < 0.01).
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Combination of ABT-869 and Radiation Inhibits Activation of the
STAT3 and Downstream Signaling Pathways
Because STAT3 is critical in regulating the expression of downstream genes
involved in apoptosis (Bcl-2, Bcl-xL, Mcl-1, survivin) and proliferation (cyclin D1),
which has also been associated with both chemo- and radio-resistance in HNSCC, we
examined the phosphorylation level of STAT3 after cells were treated with either ABT869, radiation alone or in combination by western blot analyses. STAT3 is constitutively
activated at high level in these two cell lines. Densitometry analysis demonstrated that
combination treatment significantly reduced the level of STAT3 phosphorylation (Figure
7). We next investigated the effect of ABT-869 on STAT3-regulated proteins. A
concomitant reduction of expression level of cyclin D1, Bcl-xL, Bcl-2, Mcl-1, survivin
and increased level of poly (ADP-ribose) polymerase cleavage (cPARP), a hallmark of
apoptotic cell death (Yoo et al., 2004), were observed in both cell lines.
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Figure 7. The effects of ABT-869 and radiation on STAT3 and downstream effectors in
HNSCC cells. Cells were either treated with 20 M ABT-869 or 4 Gy for 24 hrs or pretreated for 12 hrs subsequent radiation. Protein expressions were determined by western
blot. GAPDH was used as loading control. Data are the mean ± SEM of 3 independent
experiments.
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Combination of ABT-869 and Radiation Also Induces CaspaseIndependent AIF-mediated Cell Death
To identify if ABT-869 could induce caspase-independent cell death, we further
detect the expression of apoptosis inducing factor (AIF) (Figure 8). While AIF was
released to cytosol from mitochondria, later on it would translocate to the nucleus and
cause DNA fragmentation and cell death. Therefore, increased nuclear AIF expression
implies more cell death. We observed that combination of ABT-869 and radiation has
higher nuclear AIF and lower cytosolic AIF expression compared to ABT-869 alone on
both cell lines. In SCC-22B metastatic cell line, an even more obvious trend was
observed compared to primary SCC-22A cell line. Thus, combination of ABT-869 and
radiation can also induce caspase-independent AIF-mediated cell death in HNSCC.
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Figure 8. The effects of ABT-869 and radiation on cytosol & nuclear AIF expression in
HNSCC cells. Cells were either treated with 20 M ABT-869 or 4 Gy or combination for
24 hrs. Protein expressions were determined by western blot. PARP was used as nuclear
loading control for nuclear AIF. GAPDH was used as cytoplasm loading control for
cytosol AIF. Data are the mean ± SEM of 3 independent experiments.

39

Combination of ABT-869 and Radiation Increases DNA Damage Double Strand Breaks (DSBs)
We further investigate the effect of ABT-869 on DNA damage response. To
assess DNA DSBs, we examined the well documented marker γH2AX expression for
DNA double strand breaks (Bonner et al., 2008). We found that ABT-869 alone could
induce DNA damage, when combining with radiation resulted in more DNA damage.
(Figure 9) These results indicated that, inhibition of STAT3 signaling by ABT-869 could
increase DNA double strand breaks and sensitize the HNSCC cells to radiation in a
synergistic manner.
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Figure 9. The effects of ABT-869 and radiation on DNA double strand breaks in HNSCC
cells. Cells were either treated with 20 M ABT-869 or 4 Gy or combination for 24 hrs.
Protein expressions were determined by western blot. DNA double strand break marker
γH2AX was detected. GAPDH was used as loading control. Data are the mean ± SEM of
3 independent experiments.
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Discussion
Current radiation and chemotherapy protocols can control HNSCC but many
tumors do not respond well. In addition, both chemotherapy and radiotherapy have dose
limiting toxicity. Recent studies have focused on the use of novel molecular-targeted
agents with limited side effects in an attempt to improve existed treatments of HNSCC.
Targeting EGFR becomes a rational approach for HNSCC treatment since higher
expression of EGFR has been associated with resistance to radio- and/or chemo-therapy
(Bonner et al., 2006; Vermoken et al., 2008). However, such improvement on disease
control by EGFR targeting was incremental and novel targeting strategies are needed.
VEGF and its receptors are potential targets for cancer therapy and both are
expressed in increased numbers primarily during periods of tumor growth (Brekken et al.,
2000). Protection of tumor vessels by VEGF could thereby contribute to the radioresistance of tumors and high VEGF levels may additionally contribute to blood vessel
and tumor cell protection as a cause of radio-resistance (Brieger et al., 2007). Considering
the regulatory role of VEGF/PDGF as modulators of tumor growth and response to
radiation (Timke et al., 2007), we hypothesized that Linifanib (ABT-869) would
overcome radio-resistance of HNSCC cell lines. We demonstrated that ABT-869
augments head and neck cancer cells’ susceptibility to the radiation and that the cell
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growth inhibition could be achieved at lower radiation dose in combination with ABT869 in both cell lines compared to either ABT-869 or radiation alone (Figure 3), which
may prevent undesired radiation damage. To the best of our knowledge, this work shows
for the first time the synergistic effect of ABT-869 and radiation in HNSCC in vitro. The
mechanism of enhanced cell growth inhibition involves ABT-869-mediated cell cycle
arrest in G2/M phase and apoptosis.
Recent reports also showed that STAT3 can activate downstream molecules (e.g.,
c-myc, cyclin D1, Bcl family proteins, IAPs and VEGF) in HNSCC, therefore, promote
tumor cells proliferation and survival. Constitutive activation of STAT3 suppresses
apoptosis, and also has a positive correlation with cyclin D1 expression in laryngeal
carcinoma (Masuda et al., 2010). In addition, upregulation of cyclin D1, which is
involved in G1 and G2 cell cycle arrest (Michalides et al., 2002; Zhang et al., 2011), has
been specifically associated with resistance to anti-EGFR treatment and poor prognosis
of HNSCC patients. Therefore, STAT3 and cyclin D1 can be effective targets to control
the growth of cancer cells and facilitate their apoptotic death. The activity of STAT3 and
cyclin D1 expression were down-regulated after ABT-869 treatment alone and to a
greater extent in combination with radiation, which is consistent with observed G2/M cell
cycle arrest and capability to enhance the cytotoxicity of radiation. It also has been shown
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that radiation enhances STAT3 phosphorylation and increases anti-apoptotic protein
expression in several cancers (Ho et al., 2010; Lee et al., 2008). After combination
treatment of ABT-869 and radiation we detected an altered/reduced expression of STAT3
downstream effectors, Mcl-1, Bcl-2 and Bcl-xL, which have been shown to influence
radio-sensitivity (Masuda et al., 2010; Nix et al., 2005).
Several studies have documented a positive correlation between survivin, a
member of the inhibitor of apoptosis protein, tumor aggressiveness and radio-resistance
in head and neck cancer cells (Farnebo et al., 2011; Khan et al., 2010; 2012). Zhou et al.
showed that survivin is a direct target of STAT3 pathway in an AML cell line (Zhou et al.,
2009). Moreover, down-regulation of survivin can arrest cancer cells at G2/M phase and
increase caspase-dependent apoptosis (Liu et al., 2010). Our results indicated that
radiation-induced survivin expression was significantly down-regulated and the inhibition
of cell growth was correlated with significantly increased expression of cleaved PARP, a
hallmark of apoptosis, after treatment with ABT-869 alone and in combination with
radiation in SCC-22A and to a lesser extent in SCC-22B cells.
In summary, we demonstrated that ABT-869 significantly radio-sensitizes
primary and metastatic HNSCC cells (Figure 3) by inducing cell cycle arrest and cell
death. However, some differences were observed in ABT-869-induced effects between
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primary versus metastatic cell lines such as a) prolonged G2/M cell cycle arrest, b) higher
level of survivin down-regulation and c-PARP expression in primary compared to the
metastatic cell lines. This can be explained by reports of significantly higher survivin
expression in cervical lymph node metastases than in primary HNSCCs, and its negative
regulation of G2/M and apoptosis (Marioni et al., 2006; Mehlen and Puisieux, 2006).
These results suggest that the combination treatment of ABT-869 and radiation may
affect multiple pathways to induce cell death in metastatic cells, such as apoptosis
inducing factor (AIF) and endonuclease G (Endo G) mediated caspase-independent
apoptosis (Cao et al., 2012; Huerta et al., 2009). AIF can translocate from cytosol to
nucleus and cleave DNA, so we further detected the expression of nuclear AIF. The
combination of ABT-869 and radiation resulted in higher nuclear AIF and lower
cytosolic AIF expression. It implies the combination treatment can also induce caspaseindependent cell death; in SCC-22B metastatic cell line, the trend is even more obvious
than SCC-22A primary cell line. Our results are also consistent to previous studies,
showing that some reagents/compounds can affect on caspase dependent or AIF-mediated
capspase independent cell death or both pathways in various cancer types (Artus et al.,
2006; Croci et al., 2008; Jeong et al., 2011; Liu et al., 2004; Rashimi et al., 2005; Yu et
al., 2012).
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Since approximately 80% of HNSCC exhibits up-regulation of STAT3
expression, inhibition of STAT3 may cause tumor cells growth arrest and/or apoptosis.
Recent studies showed that, in colon and lung cancer cell lines, DNA damage could
induce the expression of IL-6, resulting in the activation of STAT3 signaling pathway.
Therefore, by inhibiting STAT3, one can also inhibit DNA damage repair and induce
apoptosis in tumor cells (Barry et al., 2010; Yun et al., 2012). We confirmed this
relationship by examining the expression of DNA double strand break marker γH2AX.
Inhibition of STAT3 signaling by a VEGFR/PDGFR inhibitor, ABT-869, could increase
DNA double strand breaks and synergistically sensitize HNSCC cells to radiation.
Taken together, our results serve as proof of principle that a multi-receptor
tyrosine kinase inhibitor, such as ABT-869 can be a promising radio-sensitizer and
deserve further clinical development in the treatment of HNSCC.
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CHAPTER THREE
GENERAL DISCUSSION

Targeting Angiogenesis Agents Combined with Radiation on Head
and Neck Cancer
Our study demonstrates a VEGFR/PDGFR multi-receptor tyrosine kinase
inhibitor, ABT-869, that inhibits angiogenesis can radiosensitize HNSCC cells. An
overview of current antiangiogenic agents combined with radiation on HNSCC in vitro
and in vivo studies is given in Table 1. A schematic diagram of antiangiogenic agents is
also shown in Figure 10. These studies showed that the combination of antiangiogenic
agents with radiation or chemotherapy may improve clinical responses to treat HNSCC
patients.

Postulated Mechanisms of Antiangiogenic Therapy and Radiation
The precise mechanism by which angiogenesis inhibition improves clinical
outcome is not fully understood yet. On one hand, antiangiogenic agents traditionally are
presumed to inhibit tumor vasculature formation, depriving the tumor of necessary
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nutrients and oxygen. Studies showed that the excess of EGF, VEGF and PDGF cause
poor blood flow in disorganized and leaky tumor vessels, resulting in increased IFP, and
poor drug delivery and hypoxia (Wchsberger et al., 2005). Data for head and neck cancer
suggests that bevacizumab (VEGF-A monoclonal antibody) as a single agent is not
effective in vitro, but did have in vivo activity in preclinical models. It is therefore
believed that the physiological vascular microenvironment is critical for tumor
angiogenesis (Hoang et al., 2012; Wachsberger et al., 2003). Since VEGF is a survival
factor for endothelial cells via the induction of AKT and other proteins, anti-VEGF
agents have been shown to enhance the apoptosis of endothelial cells in vitro (Gorski et
al., 1999). Given these observations, it has been proposed that anti-VEGF therapy can
enhance the ability of radiotherapy to induce destruction of tumor vasculature. There are
several possible advantages for the combination of antiangiogenic drugs with radiation to
improve cancer treatment. (1) Antiangiogenic agents are directly cytotoxic to endothelial
cells and can target VEGF and its receptors, instead of having to access the tumor
masses. (2) Decreases in the proportion of hypoxic cells and increased oxygen content
enhances oxygen-induced free radical formation resulting more DNA damage to tumor
cells. (3) Angiogenesis occurs in certain limited circumstances, like wound healing and
ovulation, therefore, antiangiogenic therapies targeting specific receptors on proliferating
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tumor endothelium will be safer and reduce normal tissue toxicities (Scappaticci et al.,
2002). Since oxygen is a potent radiosensitizer, the combination of ionizing radiation and
antiangiogenic agents would be a favorable approach. A recent study also indicated that
oxygen levels may actually increase after treatment with antiangiogenic agents and
ionizing radiation. Combination of antiangiogenesis and radiation can cause apoptosis of
both endothelial cells and tumor cells (Griffin et al., 2002; Horsman and Siemann, 2006).
(Figure 11)

Prognostic Factors / Biomarkers
Hypoxia is a characteristic pathophysiological property of locally advanced solid
tumors and such areas have been found in a wide range of human malignancies including
cancers of the prostate, pancreas, rectum, breast, uterine cervix, brain tumors, malignant
melanomas and head & neck cancers. Molecular studies investigating the tissue
distribution of HIF-1α and of its target proteins CA-9 and GLUT-1 showed worse
outcomes in cases exhibiting an overexpression of these endogenous markers (Evans et
al., 2003; Vaupel et al., 2002; 2004). Lactate accumulation is another factor proportional
to malignant levels and increased risk of metastases in head and neck cancer, cervical
cancer, and colorectal cancer (Brizel et al., 2001; Walenta et al., 2000; 2003).
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Overexpression of EGFR is detected in 90 % of all HNSCC tumors, and high levels of
this protein expression is associated with decreased survival, radio-resistance, increased
rates of distant metastases and recurrence (Dorsey and Agulnik, 2013). In a meta-analysis
of 12 studies, including 1002 patients of oral cavity, pharyngeal and laryngeal cancers,
higher VEGF expression showed positive association with a 2-fold higher risk of death
within 2 years (Kyzas et al., 2005). VEGF plasma levels have been described as potential
prognostic and predictive biomarkers as well (Allen et al., 2005; Druzgal et al., 2005).
Other factors like VEGFR/KDR, pKDR/KDR, Bax, BcL-xL, BcL-2, cyclooxygenase-2
(COX-2) and survivin, all correlated to clinical outcomes in retrospective clinical studies
(Cohen et al., 2009; Farnebo et al., 2011; Seiwert and Cohen, 2008). A recent study also
showed that vascular normalization induced by antiangiogenic therapies can stimulate
tumor microenvironmental immune response, thus, enhance cancer immunotherapy to
kill cancer cells (Huang et al., 2012). An increase in tumor-infiltrating CD8+ T cells
could be a potential biomarker for vascular normalization (Huang et al., 2013). Thus, it is
critical to validate these potential biomarkers in perspective randomized studies.
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Conclusions
Despite recent advances in therapy for head and neck squamous cell carcinoma,
chemotherapeutics cytotoxicity is of major concern. Novel therapy with targeted agents is
a promising direction. There are some practical points needed to be considered. These
agents have a cytostatic function but not curative potential, theoretically should be used
in combination with radiation or other chemo-therapies instead of single therapy to
achieve appreciable impact on patient survival (Loges et al., 2009). Increasing the dose of
antiangiogenic agent or double antiangiogenic agent combination treatment might do
harm to normal tissues and destroy vasculature due to rapid/excessive pruning of tumor
vessels, leading to hypoxia and poor drug delivery in the tumor (Jain, 2005). Thus,
optimal doses and schedules of these reagents tailored to the angiogenic profile of tumors
can normalize tumor vasculature and its microenvironment without harming normal
tissues. Combining ABT-869 with other chemo-drugs/DNA damaging agents like
cisplatin and 5-Fluorouracil or PARP inhibitor to result in more persistent DNA double
strand breaks might mimic the results of this study. Here, we have shown
VEGFR/PDGFR multi-receptor tyrosine kinase inhibitor, ABT-869, is an attractive
option to overcome radioresistance. Antiangiogenic therapy in combination with
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radiotherapy is a promising strategy, which could lead to less morbidity and increased
efficacy in the treatment of HNSCC.
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Figure 10. The effects of antiangiogenic agents on cell signaling pathways that lead to
enhanced radiosensitivity.
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Figure 11. Possible advantages and mechanisms of using antiangiogenic therapies to
enhance tumor response to radiation. These agents can improve tumor oxygenation via
targeting tumor vasculature and inhibiting new vessel formation, also disrupt the
interaction between tumor cells and tumor endothelial cells. When combining with
ionizing radiation, it results in both tumor and endothelial cell apoptosis, work
synergistically to improve radiosensitization effects.
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